Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Downgrades CME Group to Market Perform

Raymond James analyst Patrick O'Shaughnessy downgrades CME Group (NASDAQ:CME) from Outperform to Market Perform.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Raymond James analyst Patrick O’Shaughnessy downgrades CME Group (NASDAQ:CME) from Outperform to Market Perform.

Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $67

By Benzinga Newsdesk

Today, 3:05 AM

Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $72 to $67.

BCYC

Moderna’s COVID-19 Shot Gets EMA’s Backing For Use In Adolescents

By Vandana Singh

Today, 3:05 AM

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of Moderna…

MRNA

B of A Securities Upgrades JM Smucker to Buy, Raises Price Target to $155

By Benzinga Newsdesk

Today, 3:05 AM

B of A Securities analyst Peter Galbo upgrades JM Smucker (NYSE:SJM) from Neutral to Buy and raises the price target from $145 to $155.

SJM

E.L.F. Beauty Sees FY22 Net Sales $357M-$364M Vs $343M-$350M Prior

By Benzinga Newsdesk

Today, 3:05 AM

The Company is providing the following updated outlook for fiscal 2022. When compared to fiscal 2021, the updated outlook for fiscal 2022 reflects an expected 12-14% increase in net sales,

ELF

Raymond James Downgrades CME Group to Market Perform

Related Posts

Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $67

Moderna’s COVID-19 Shot Gets EMA’s Backing For Use In Adolescents

B of A Securities Upgrades JM Smucker to Buy, Raises Price Target to $155

E.L.F. Beauty Sees FY22 Net Sales $357M-$364M Vs $343M-$350M Prior